Novellia Raises $18M Series A Round

Novellia has secured $18 million in Series A funding, with the round led by prominent venture capital firm Spark Capital. The financing round included participation from a notable syndicate of healthcare and technology investors: Khosla Ventures, Acrew Capital, Bling Capital, and TMV. This Series A brings Novellia's cumulative funding to $28 million, indicating strong investor conviction in the company's market opportunity and execution to date.

The company operates in the healthcare data infrastructure space, positioning itself as a patient-consented real-world data platform. Unlike traditional health data aggregators, Novellia's differentiation centers on voluntary patient participation—the company collects and unifies health information only from individuals who explicitly choose to contribute their data to medical research. This consent-based model addresses growing regulatory scrutiny and privacy concerns in healthcare data handling, particularly relevant given evolving HIPAA interpretations and state-level privacy legislation.

Novellia's core product enables patients to aggregate and access their complete health histories spanning over two decades, consolidating records that typically exist in fragmented form across multiple healthcare providers, insurance companies, and clinical systems. The company is leveraging this capability to accelerate drug development and clinical research by providing pharma companies and researchers with validated, real-world patient cohorts. The launch of Novellia's patient-facing mobile application extends its existing online platform, potentially broadening user adoption and engagement metrics critical for a data-aggregation business model.

The company has achieved meaningful third-party validation through industry awards and clinical publication. Novellia was recognized by Digital Health New York as one of 10 startups to watch, won a 2026 Fierce Outsourcing Award for Innovation in Drug Development, and received a 2026 MedTech Breakthrough Award for Best Healthcare Data Repository Solution. Its clinical credibility is further supported by peer-reviewed research presented at major medical conferences including ASCO and SABCS-AACR, demonstrating tangible utilization of its data assets in oncology and oncology-related research.

For institutional investors, Novellia represents exposure to the healthcare data infrastructure and real-world evidence market, segments experiencing significant growth as pharmaceutical companies increasingly rely on non-traditional data sources for clinical development and post-market surveillance. The company's consent-based model mitigates regulatory risk relative to competitors operating in more legally ambiguous territory.